Publications by authors named "Matthew W Harding"

Claim this Profile
A
A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers.
J Michael Hamilton, Matthew W Harding, Thomas Genna, David K Bol

J Clin Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
Leena Gandhi, Matthew W Harding, Marcus Neubauer, Corey J Langer, Melvin Moore

Cancer· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
Farid Gizatullin, Yao Yao, Victor Kung, Matthew W Harding, Massimo Loda

Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.
Matthew W Harding

Clin Cancer Res· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Randall P Rago, Albert Einstein, Richard Lush, Tomasz M Beer, Yoo-Joung Ko, Matthew W Harding

Cancer Chemother Pharmacol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.
Michael V Seiden, Kenneth D Swenerton, Ursula Matulonis, Susan Campos, Peter Rose, Matthew W Harding

Gynecol Oncol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
Deborah Toppmeyer, Andrew D Seidman, Michael Pollak, Christy Russell, Katherine Tkaczuk, Matthew W Harding

Clin Cancer Res· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Vivien H C Bramwell, Donald Morris, D Scott Ernst, Ingrid Hings, Martin Blackstein, Matthew W Harding

Clin Cancer Res· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis